Roche: new positive results in NSCLC
(CercleFinance.com) - Roche today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival and progression-free survival for a first-line treatment of non-small cell lung cancer (NSCLC).
The combination Tecentriq (atezolizumab) plus chemotherapy helped people with metastatic non-squamous NSCLC live significantly longer, reducing the risk of the disease worsening or death, compared with chemotherapy alone.
The Swiss laboratory points out that this is the third phase III study evaluating its Tecentriq, alone or in combination, demonstrating a benefit in terms of overall survival in patients with non-small cell lung cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The combination Tecentriq (atezolizumab) plus chemotherapy helped people with metastatic non-squamous NSCLC live significantly longer, reducing the risk of the disease worsening or death, compared with chemotherapy alone.
The Swiss laboratory points out that this is the third phase III study evaluating its Tecentriq, alone or in combination, demonstrating a benefit in terms of overall survival in patients with non-small cell lung cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.